Figure 6.
PRC1 contributes to BC by inhibiting expression of BC tumor suppressors. CFAs of K562 and KCL22 cells retrovirally transduced with (A) EGR1, either wild-type (WT) or dominant negative (DN) or (C) the indicated cDNAs are shown. (A) *P = .001; **P = .00004; #P = .03; ##P = .04. (C) *P = .000001; **P = .0011; #P = .000003; ##P = .003. CFAs of K562, KCL22 (E), and primary BC cells (G) retrovirally transduced with FLAG-NR4A2, either wild-type (WT) or (C283G) mutant are shown. (E) *P = .0009; **P = .0022; #P = .027. (G) *P = .0021. For panels A, C, E, and G, results are given as mean ± standard deviation (n = 3). For each CFA plot, the corresponding immunoblots are shown on the right (B,D,F,H). Control, cells retrovirally transduced with empty vector.